Earlier this year, U.S. Congress passed a law that requires the submission of a diversity plan for late-stage drug trials and the development of guidance to “encourage meaningful diversity among clinical trial participants, including with respect to race, ethnicity, age, sex, and geographic location, as appropriate.” This law marks a big step…
Read More